Search | Clinical Trials Finder

Conditions: Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
Interventions: Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High; Drug
Lead sponsor: ARKAY Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Albany, New York

Conditions: Healthy
Interventions: Metformin Hydrochloride ER Tablets 500 mg, Glucophage® XR Tablets 500 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy Volunteers
Interventions: CANA/MET XR FDC; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Healthy
Interventions: Metformin HCl 750 mg Extender Release tablets, single dose, GLUCOPHAGE® XR 750 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: Dapagliflozin, Metformin XR, Glucophage; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: metformin HC1 750 mg extended-release tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Osteoarthritis, Knee, Post-traumatic Osteoarthritis, ACL Tear
Interventions: Metformin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: Atlanta, Georgia • Iowa City, Iowa • Lexington, Kentucky + 6 more

Conditions: Low Milk Supply, Pre-diabetes, Insulin Resistance, Suppressed Lactation
Interventions: Standard care, Metformin, Placebo; Behavioral · Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 20 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: Metformin Hydrochloride ER Tablets 750 mg, Glucophage® XR Tablets 750 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Polycystic Ovary Syndrome, Infertility, Pregnancy
Interventions: metformin XR, clomiphene citrate; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 11
States / cities: Birmingham, Alabama • La Jolla, California • Stanford, California + 8 more

Conditions: Genetics, Metabolism, Type 2 Diabetes
Interventions: Mixed Meal Tolerance Test, Metformin; Other · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 79 Years
Enrollment: 1,017 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer, Prostate Cancer Recurrent
Interventions: Metformin Hydrochloride Extended Release 750mg; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 52
States / cities: Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more

Conditions: Healthy
Interventions: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Colorectal Neoplasms
Interventions: Placebo, Metformin; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Little Rock, Arkansas

Conditions: Healthy
Interventions: Trospium Chloride (Sanctura XR®), Metformin hydrochloride (Glucophage®); Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Type 2 Diabetes Mellitus
Interventions: Metformin immediate release (IR), Saxagliptin, Metformin IR, Saxagliptin/Metformin XR FDC, Metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Little Rock, Arkansas • Los Angeles, California • Louisville, Kentucky + 3 more

Conditions: Hyperemesis Gravidarum
Interventions: Metformin Extended Release Oral Tablet; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Birmingham, Alabama • Los Angeles, California

Conditions: Prediabetic State, Atherosclerosis, Metformin
Interventions: Metformin XR, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 7,410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more

Conditions: Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma, Microsatellite Instability-High Solid Malignant Tumor
Interventions: Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone; Drug
Lead sponsor: Dan Zandberg; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions: Metformin XR, Placebo; Drug · Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 3 more

Conditions: Type 2 Diabetes Mellitus
Interventions: 2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Prevention in Women After GDM Who Are at High-risk
Interventions: DAPA/MET XR, DAPA, MET XR; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Metformin XR, Placebo matching Metformin XR, Placebo matching Saxagliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 12
States / cities: Phoenix, Arizona • Redlands, California • Tustin, California + 9 more

Search by objective public record fields.

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

Fasting Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg

Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Fasting Conditions

Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

Bioequivalence Study of Metformin HCl 750 mg XR Under Fasting Conditions

Preventing Injured Knees From osteoArthritis: Severity Outcomes

Metformin to Augment Low Milk Supply (MALMS) Study

Fasting Study of Metformin Hydrochloride ER Tablets 750 mg and Glucophage® XR Tablets 750 mg

Treatment of Infertility in Women With Polycystic Ovary Syndrome

Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS

Metformin Prostate Cancer Adjuvant Trial

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth

Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

Hyperemesis Gravidarum Risk Reduction With Metformin

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women

Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg